How to handle use of additional medication for Alzheimer’s Disease during randomised clinical trials?

• Published in: Alzheimer's & dementia Vol. 20; no. S6
• Main Authors: Dethlefsen, Claus, Johannsen, Peter
• Format: Journal Article
• Language: English
• Published: Hoboken John Wiley and Sons Inc 01.12.2024
• Subjects: Drug Development

Background Phase 3 randomized clinical trials within Alzheimer’s Disease (AD) typically last over 18 months. Post‐baseline participants can use additional treatment for Alzheimer’s disease, potentially impacting the cognitive ability as evaluated by the primary endpoint. Consequently, this could ove...